Beaufort Securities reissued their speculative buy rating on shares of Tiziana Life Sciences PLC (LON:TILS) in a research report sent to investors on Monday. They currently have a GBX 400 ($5.31) target price on the biotechnology company’s stock.

Shares of Tiziana Life Sciences PLC (LON TILS) opened at 150.00 on Monday. The company has a 50-day moving average of GBX 154.01 and a 200-day moving average of GBX 179.35. Tiziana Life Sciences PLC has a 12-month low of GBX 102.06 and a 12-month high of GBX 240.00. The stock’s market capitalization is GBX 141.59 million.

Tiziana Life Sciences PLC (LON:TILS) last released its earnings results on Friday, September 29th. The biotechnology company reported GBX (4.10) (($0.05)) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of GBX (2) (($0.03)) by GBX (2.10) (($0.03)). Equities analysts expect that Tiziana Life Sciences PLC will post ($1.70) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Tiziana Life Sciences PLC (TILS) Given “Speculative Buy” Rating at Beaufort Securities” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at

About Tiziana Life Sciences PLC

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.

Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.